Louis P Garrison|Bruce C M Wang - JoVE Visualize

Showing results (171-180 of 186) with videos related to

Pageof 19

Sort By:

Pain and Therapy|March 3, 2016

The Cost-Effectiveness of Pregabalin Versus Gabapentin for Peripheral Neuropathic Pain (pNeP) and Postherpetic Neuralgia (PHN) in ChinaBruce C M Wang, Dongdong Liu, Wesley E Furnback, et al.

Drugs - Real World Outcomes|October 18, 2016

Estimating the Economic Burden of Rheumatoid Arthritis in Taiwan Using the National Health Insurance DatabaseBruce C M Wang, Ping-Ning Hsu, Wesley Furnback, et al.

Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|October 12, 2015

Estimating the cost-effectiveness of linezolid for the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia in TaiwanPo-Chang Lin, Bruce C M Wang, Richard Kim, et al.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 26, 2018

A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]Louis P Garrison, Peter J Neumann, Richard J Willke, et al.

Clinicoeconomics and Outcomes Research : CEOR|February 11, 2025

Estimating the Cost-Effectiveness of Tumor Treating Fields (TTFields) Therapy with an Immune Checkpoint Inhibitor or Docetaxel in Metastatic Non-Small Cell Lung CancerWesley Furnback, Elizabeth Wu, Cloe Ying Chee Koh, et al.

Plos One|July 26, 2018

Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in ChinaKunling Shen, Matthew Wasserman, Dongdong Liu, et al.

Journal of Medical Economics|June 11, 2025

Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United StatesLucio N Gordan, Arielle G Bensimon, Fan Mu, et al.

Transfusion|September 10, 2021

Relationship between transfusion burden, healthcare resource utilization, and complications in patients with beta-thalassemia in Taiwan: A real-world analysisChao-Hsiun Tang, Wesley Furnback, Bruce C M Wang, et al.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 28, 2021

Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?Abigail R Colson, Alec Morton, Christine Årdal, et al.

Vaccines|July 27, 2024

Capturing the Value of Vaccination within Health Technology Assessment and Health Economics-Practical Considerations for Expanding Valuation by Including Key ConceptsEliana Biundo, Mariia Dronova, Annie Chicoye, et al.

Pageof 19

Showing results (171-180 of 186) with videos related to

Sort By:

Pageof 19

Pain and Therapy|March 3, 2016

The Cost-Effectiveness of Pregabalin Versus Gabapentin for Peripheral Neuropathic Pain (pNeP) and Postherpetic Neuralgia (PHN) in ChinaBruce C M Wang, Dongdong Liu, Wesley E Furnback, et al.

Drugs - Real World Outcomes|October 18, 2016

Estimating the Economic Burden of Rheumatoid Arthritis in Taiwan Using the National Health Insurance DatabaseBruce C M Wang, Ping-Ning Hsu, Wesley Furnback, et al.

Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|October 12, 2015

Estimating the cost-effectiveness of linezolid for the treatment of methicillin-resistant Staphylococcus aureus nosocomial pneumonia in TaiwanPo-Chang Lin, Bruce C M Wang, Richard Kim, et al.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|February 26, 2018

A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]Louis P Garrison, Peter J Neumann, Richard J Willke, et al.

Clinicoeconomics and Outcomes Research : CEOR|February 11, 2025

Estimating the Cost-Effectiveness of Tumor Treating Fields (TTFields) Therapy with an Immune Checkpoint Inhibitor or Docetaxel in Metastatic Non-Small Cell Lung CancerWesley Furnback, Elizabeth Wu, Cloe Ying Chee Koh, et al.

Plos One|July 26, 2018

Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in ChinaKunling Shen, Matthew Wasserman, Dongdong Liu, et al.

Journal of Medical Economics|June 11, 2025

Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United StatesLucio N Gordan, Arielle G Bensimon, Fan Mu, et al.

Transfusion|September 10, 2021

Relationship between transfusion burden, healthcare resource utilization, and complications in patients with beta-thalassemia in Taiwan: A real-world analysisChao-Hsiun Tang, Wesley Furnback, Bruce C M Wang, et al.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 28, 2021

Antimicrobial Resistance: Is Health Technology Assessment Part of the Solution or Part of the Problem?Abigail R Colson, Alec Morton, Christine Årdal, et al.

Vaccines|July 27, 2024

Capturing the Value of Vaccination within Health Technology Assessment and Health Economics-Practical Considerations for Expanding Valuation by Including Key ConceptsEliana Biundo, Mariia Dronova, Annie Chicoye, et al.

Pageof 19